Indeed, patients with lower levels of POPX2 showed lower overall survival rate and lower relapse-free survival.9 Therefore, a combination therapy targeting TAK1-IKK-NF-κB pathway may help to increase the effectiveness of cancer treatment. This evidence concerns the gene NFKB1 and cancer.